Abstract Details

Title Treatment Outcomes Among Amyotrophic Lateral Sclerosis Patients Receiving Intravenous Edaravone (IV): 44 Months of Follow-up From US Specialty Infusion Centers

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P2 - Poster Session 2 (11:45 AM-12:45 PM)

Poster/Presentation
Number 11-005

Objective To describe real-world treatment outcomes in patients treated with IV edaravone collected by 2 providers of home/alternative-site infusions over a period of 44 months.

Background As 1 of only 2 drug therapies approved for treatment of amyotrophic lateral sclerosis (ALS) in the US, IV edaravone (FDA approved in May 2017) became available to US healthcare providers in August 2017. Information on real-world effectiveness of IV edaravone is limited.

Design/Methods A retrospective cohort study was conducted utilizing de-identified data collected from two providers of home/alternative-site infusions and specialty pharmacy services that treat patients receiving IV edaravone across the US. ALS patients receiving their first IV edaravone dose between August 8, 2017, and December 31, 2020, were selected. Variables collected included demographic information, ALS Functional Rating Scale-Revised (ALSFRS-R) and Forced Vital Capacity (FVC) scores, and quality-of-life measures such as energy levels, sleep patterns, stress levels, mood, and overall health and wellness. All variables were assessed descriptively.

Results A total of 455 patients were included in the analysis; 52.1% were male and 33.6% were between the ages of 60-69 at the start of treatment at the center. In patients who had physician-recorded ALSFRS-R (n=89) and FVC scores (n=63) at the start of treatment, the mean±SD was 34.3±9.3 and 70.7%±21.6%, respectively. At the end of the study period, 217 (47.6%) patients discontinued treatment. The most frequent reason for discontinuation was death or hospice, 76 (35.0%); followed by patient choice, 60 (27.6%); insurance or care change, 42 (19.4%); doctor choice, 20 (9.2%); and other, 19 (8.8%).

Conclusions This analysis described treatment outcomes in patients with ALS treated with IV edaravone since FDA approval. It is hoped that this information will be useful to clinicians who prescribe IV edaravone for their patients with ALS.

Authors/Disclosures
Malgorzata Ciepielewska PRESENTER	Malgorzata Ciepielewska has received personal compensation for serving as an employee of Mitsubishi Tanable Pharma America, Inc..
Melissa Hagan (Mitsubishi Tanabe Pharma America, Inc)	Melissa Hagan has received personal compensation for serving as an employee of Mitsubishi Tanabe Pharma America, Inc..
Polina Da Silva, Other (Mitsubishi Tanabe Pharma America)	Mrs. Da Silva has nothing to disclose.
Ying Liu	Ying Liu has nothing to disclose.
Jeffrey Zhang (Princeton Pharmatech LLC.)	The institution of Jeffrey Zhang has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for BioVie.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Stephen Apple	Stephen Apple has received personal compensation for serving as an employee of Mitsubishi Tanabe Pharma America, Inc.

��ɫ��

��ɫ��